European Medicines Agency mid-year report 2023 (January-June 2023)
European Medicines Agency mid-year report 2023 (January-June 2023)
European Medicines Agency mid-year report 2023 (January-June 2023)
List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs)
Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Carcinoma, Non-Small-Cell Lung;Mesothelioma, Date of authorisation: 18/01/2016, Revision: 14, Status: Authorised
Workshop on generating clinical evidence for treatment and prevention options for long-COVID and post-acute sequelae condition (PASC), Online, 13:00 - 18:00 Amsterdam time (CET), from 17/11/2023 to 17/11/2023
Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/202302
Trulicity (dulaglutide) supply shortage
Human medicines European public assessment report (EPAR): Filsuvez, birch bark extract, Epidermolysis Bullosa Dystrophica;Epidermolysis Bullosa, Junctional, Date of authorisation: 21/06/2022, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Xeplion, paliperidone, Schizophrenia, Date of authorisation: 04/03/2011, Revision: 16, Status: Authorised
COVID-19 guidance: research and development
Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts